Active ingredientVarespladibCat. No. P-V020-001CAS 172732-68-2Family · Pharmaceutical analytical standards
Varespladib
An inhibitor of secretory phospholipases A2 created for inflammatory and cardiovascular diseases, whose development in cardiology stopped in 2012 for insufficient efficacy; since 2016 it has been studied as a possible antidote to snake venom. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It also exists in an oral form, varespladib methyl, which could be taken straight after a bite, before reaching hospital; in 2019 the FDA granted it orphan drug designation for this use.
Go to the active ingredient →Active ingredientVarespladibCat. No. P-V020-001CAS 172732-68-2
Isotopically labelledVarespladib-d5Cat. No. P-V020-002
Isotopically labelledVarespladib-d7Cat. No. P-V020-003CAS 1360701-64-9
ImpurityVarespladib MethylCat. No. P-V020-004CAS 172733-08-3No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.